ClinicalTrials.gg
RecruitingNCT06926751Updated May 7, 2026

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

A Phase 2 interventional study of Telpegfilgrastim Injection and filgrastim in Solid Tumors, Children and Adolescent, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 6 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
6 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Neutropenia with a site in China — 11 open to participants now, 12 under way, 1 of them phase 3. Neutropenia · China.

Planned enrollment
16th of 36
132 · median 119
Started
2025
with 5 others
Phase 2
13 of 42
4 open now
Primary completion
2027-04
later than 8 of 11 live
Registered
35th of 42
by date
Lead sponsor
2 of 42
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 42 studies in Neutropenia with a site in China, this one is the 16th largest by planned enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 35th registered.

Neutropenia

316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.

Browse Neutropenia studies →

Open to participants now

11 of the 42 studies in Neutropenia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neutropenia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Telpegfilgrastim (a PEGylated recombinant human granulocyte colony-stimulating factor, PEG-rhG-CSF) compared to Filgrastim (short-acting rhG-CSF) in preventing chemotherapy-induced neutropenia (CIN) in children and adolescents aged 6-24 years with malignant solid tumors receiving high-intensity chemotherapy regimens. The main questions it aims to answer are:

  • Does Tuopefilgrastim reduce the incidence of febrile neutropenia (FN) in the first chemotherapy cycle (Cx+1) compared to Filgrastim?
  • How do the two treatments compare in terms of duration and severity of neutropenia, chemotherapy delays/dose reductions, antibiotic use, and bone pain incidence? Researchers will compare the Telpegfilgrastim group (3:1 ratio, 99 participants) with the Filgrastim group (33 participants) to determine if Telpegfilgrastim demonstrates superior efficacy and safety.

Participants will:

  • Receive subcutaneous injections of either Telpegfilgrastim (33 μg/kg, single dose) or Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle.
  • Undergo blood tests, physical exams, and temperature monitoring during follow-up visits.
  • Be assessed for bone pain severity using age-appropriate scales (FLACC or Wong-Baker).
  • Complete two chemotherapy cycles with close safety and efficacy monitoring.
Read the detailed description

This multicenter, randomized, open-label, controlled clinical trial evaluates the efficacy and safety of Telpegfilgrastim, a novel 40kD Y-branched PEGylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), compared to Filgrastim (short-acting rhG-CSF) in preventing chemotherapy-induced neutropenia (CIN) among pediatric and adolescent patients (aged 6-24 years) with malignant solid tumors receiving high-intensity chemotherapy. The study employs a two-phase adaptive design: Phase 1 involves 20 participants (15 in the Telpegfilgrastim arm, 5 in the Filgrastim arm) to assess preliminary pharmacokinetics (PK) and safety, including drug half-life (71.7 ± 23 hours for Telpegfilgrastim vs. 3.5-4 hours for Filgrastim) and neutrophil recovery dynamics, with potential dose adjustments before progressing to Phase 2. The full trial enrolls 132 participants randomized 3:1 (99 vs. 33), stratified by age subgroups (6-12, 13-18, 19-24 years) to account for developmental variations in drug metabolism. Telpegfilgrastim is administered as a single subcutaneous injection (33 μg/kg, max 2 mg) 24 hours post-chemotherapy, leveraging its prolonged activity from Y-shaped PEGylation, while Filgrastim requires daily injections (5 μg/kg/day) until absolute neutrophil count (ANC) recovers to ≥10.0×10⁹/L. Concomitant use of other myelostimulatory agents (e.g., GM-CSF, trilaciclib) is prohibited to isolate treatment effects.

Neutrophil monitoring includes ANC measurements at baseline and days 7, 9, 11, 13, 15, and 21 (±1 day) post-chemotherapy using standardized hematology analyzers. Febrile neutropenia (FN) is strictly defined as ANC \<0.5×10⁹/L (Grade 4) or ANC 0.5-\<1.0×10⁹/L (Grade 3) with anticipated decline to \<0.5×10⁹/L within 48 hours, accompanied by axillary temperature ≥37.7°C sustained for ≥1 hour. Bone pain, a key safety focus, is assessed using age-specific tools: the FLACC scale (Face, Legs, Activity, Cry, Consolability; 0-10) for children \<8 years and the Wong-Baker Faces Pain Rating Scale (0-10) for older participants. Exploratory analyses evaluate bone metabolism through serial serum osteocalcin (osteoblast activity marker) and RANKL/OPG ratio (osteoclast regulation) measurements at baseline, day 7, and day 21, with optional bone marrow aspirates to assess hematopoietic stem/progenitor cell (HSPC) mobilization efficiency.

Data management utilizes a validated electronic data capture (EDC) system with real-time entry and automated queries for anomalies, complemented by source data verification (SDV) for ≥20% of cases, prioritizing primary endpoints and serious adverse events (SAEs). Sample size (132 participants) is calculated based on prior pediatric FN incidence rates (45% PEG-rhG-CSF vs. 75% rhG-CSF), with α=0.05, 80% power, and 20% attrition. Statistical analyses employ the Full Analysis Set (FAS, intent-to-treat) and Per-Protocol Set (PPS), using ANOVA or nonparametric tests for continuous variables (e.g., ANC recovery time) and Chi-square/Fisher's exact tests for categorical outcomes (e.g., FN incidence), adjusted for age, tumor type, and chemotherapy regimen. Safety analyses include all participants receiving ≥1 dose (Safety Set), with SAEs reported per ICH-GCP and China NMPA guidelines, monitored by an independent Data Safety Monitoring Board (DSMB).

Ethical compliance is ensured through institutional review board (IRB) approvals at all 16 participating centers, emphasizing informed consent/assent for adolescents, anonymized biological sample storage (≤5 years post-trial), and voluntary withdrawal rights. The trial's innovation lies in its focus on pediatric PK/PD profiling, addressing faster drug clearance in children, and evaluating long-term skeletal safety via bone metabolism biomarkers-critical for growing populations. By comparing next-generation PEG-rhG-CSF with conventional rhG-CSF, this study aims to refine global supportive care guidelines for pediatric oncology, balancing efficacy and safety in high-intensity chemotherapy settings.

03

Conditions studied

  • Solid Tumors
  • Children
  • Adolescent
  • Chemotherapy Induced Neutropenia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed malignant solid tumor requiring high-intensity chemotherapy, with ≥2 remaining chemotherapy cycles, and either:

    • Previous febrile neutropenia(FN) or dose-limiting neutropenia in the prior chemotherapy cycle without prophylactic granulocyte colony-stimulating factor (G-CSF);
    • Previous FN or dose-limiting neutropenia in the prior chemotherapy cycle despite prophylactic G-CSF.
  2. Age ≥6 to ≤24 years.
  3. Performance Status ≤1.
  4. Normal bone marrow hematopoietic function: ≥75 g/L, white blood cell count ≥3.0×10\^9/L, ≥80×10\^9/L, and neutrophils ≥1.5×10\^9/L.
  5. Anticipated survival ≥8 months.
  6. Willing to participate, with written signed by the patient or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Bone marrow involvement at screening.
  2. Uncontrolled localized or systemic infection.
  3. Known to Telpegfilgrastim, recombinant human granulocyte-colony stimulating factor(rhG-CSF), or other pegylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF) agents.
  4. Concurrent participation in any other drug or device trial.
  5. Severe organ dysfunction: total , (ALT), or aspartate transaminase(AST) >2.5 × (ULN) (or >5 × ULN in patients with liver ), serum creatinine >5 × ULN.
  6. Severe psychiatric disorders affecting provision or adverse event assessment.
  7. Any condition deemed by the investigator to compromise patient safety or interfere with study outcomes, including risks from the investigational product or confounding adverse event evaluation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Telpegfilgrastim

    Receive subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle

    Drug: Telpegfilgrastim Injection

  • Active comparator
    Filgrastim

    Receive subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle

    Drug: filgrastim

Interventions

  • DrugTelpegfilgrastimStudies of TelpegfilgrastimTelpegfilgrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    subcutaneous injections of Telpegfilgrastim (33 μg/kg, single dose) 24 hours after each chemotherapy cycle

    Also known as: Y-branched pegylated recombinant human granulocyte colony stimulating factor, YPEG-G-CSF, Peijin

  • subcutaneous injections of Filgrastim (5 μg/kg/day, multiple doses) 24 hours after each chemotherapy cycle

    Also known as: Recombinant Human Granulocyte-Colony Stimulating Factor, rhG-CSF, Topneuter

06

What researchers measure

Primary outcomes

  1. Incidence of febrile neutropenia in Cycle 1

    Incidence of febrile neutropenia in Cycle 1 (i.e., the first chemotherapy cycle post-enrollment)

    Time frame: 21-28 days

Secondary outcomes

  1. Incidence of grade 3 neutropenia during Cycles 1-2

    Incidence of grade 3 neutropenia (absolute neutrophil count\<1.0×10\^9/L) during Cycles 1-2

    Time frame: 42-56 days

  2. Time to recovery of grade 3 neutropenia during Cycles 1-2

    Time to recovery of grade 3 neutropenia (absolute neutrophil count\<1.0×10\^9/L) during Cycles 1-2

    Time frame: 42-56 days

  3. Time to recovery of grade 4 neutropenia during Cycles 1-2

    Time to recovery of grade 4 neutropenia (absolute neutrophil count \<0.5×10\^9/L) during Cycles 1-2

    Time frame: 42-56 days

  4. Incidence of grade 4 neutropenia during Cycles 1-2

    Incidence of grade 4 neutropenia (absolute neutrophil count \<0.5×10\^9/L) during Cycles 1-2

    Time frame: 42-56 days

  5. Incidence of febrile neutropenia during Cycle 2

    Incidence of febrile neutropenia during Cycle 2 (i.e., the second chemotherapy cycle post-enrollment)

    Time frame: 21-28 days

  6. Proportion of patients with chemotherapy delay or dose reduction in subsequent cycles due to neutropenia during Cycles 1-2

    Proportion of patients with chemotherapy delay or dose reduction in subsequent cycles due to neutropenia during Cycles 1-2

    Time frame: 42-56 days

  7. Proportion of patients receiving antibiotic treatment and experiencing infections during Cycles 1-2

    Proportion of patients receiving antibiotic treatment and experiencing infections during Cycles 1-2

    Time frame: 42-56 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 25 phase 2 interventional studies under Neutropenia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Apr 15, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Sep 1, 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06926751
Responsible party
SIDAN LI (Prof, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Apr 15, 2025
Start date
Jun 12, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 7, 2026

Study contacts

Sidan Li
Contact
lisidan2006@126.com
+86-0316-5917421
Sidan Li
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telpegfilgrastim

Start the discussion